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Introduction. The pathogenesis of GERD is strongly related with mixed acid and bile reﬂux. Benign and malignant esophageal
and gastric lesions have been associated with synergetic activity between those parameters. Bile reﬂux causes reactive gastropathy
evaluated with Bile Reﬂux Index (BRI). The aim was to investigate if the sequence: bile reﬂux-intestinal metaplasia-GERD-
esophagitis,isassociatedwithapoptotic/oncogeneticdisturbances.Materials/Methods.Fifteenasymptomaticsubjectsand53GERD
patients underwent gastroscopy with biopsies. The specimens examined histologically and immunohistochemically for p53, Ki-
67, Bax, and Bcl-2. Results. Elevated BRI score detected in 47% (25/53) of patients with GERD and in 13% (2/15) of controls
(P = 0.02). Severe esophageal lesions were signiﬁcantly more common in BRI (+) patients (14/25) compared to BRI (−) ones
(P = 0.0049).ImmunohistochemicalanalysisdidnotshowassociationsbetweenBRIscoreandbiomarkerexpression.Conclusions.
Bile reﬂux gastropathy is associated with GERD severity, but not with oncogene expression or apoptotic discrepancies of the upper
GI mucosa.
1.Introduction
The gastroesophageal reﬂux disease (GERD) represents one
of the most common gastrointestinal disorders, especially in
the western countries [1, 2]. It is the result of the exposure
of the esophageal mucosa to acidic gastric juice and/or bile-
containing duodenal reﬂuxates via an incompetent lower
esophageal sphincter. The acid and bile exposure times, as
demonstrated by 24h monitoring methodologies, greatly
overlap among the cases of GERD with diverse endoscopic
ﬁndings ranging from normal mucosa (nonerosive reﬂux
disease (NERD)) to severe reﬂux oesophagitis, Barrett’s
e s o p h a g u s ,a n dc o m p l i c a t i o n ss u c ha ss t r i c t u r e so ru l c e r s[ 3–
6].
Although in the past the pathogenesis of GERD was
strongly associated with the gastric acid, during the last
two decades the role of mixed reﬂux has been increas-
ingly investigated. The synergetic activity between acid and
bile has largely been implicated in the clinical spectrum
of GERD and methods such as Bilitec 2000 and the
multichannel intraluminal impedance are nowadays widely
used towards the thorough evaluation of the disorder
[7]. The highest esophageal exposure to bile has been
observed in patients with Barrett’s dysplasia and esophageal
adenocarcinoma. However, it has also been associated
with erosive oesophagitis, Barrett’s esophagus without dys-
plasia, and intestinal metaplasia of the gastric antrum
[8–15].2 Gastroenterology Research and Practice
The passage of duodenal contents through the stom-
ach produces consistent histological changes in the gas-
tric mucosa (reactive gastropathy) with antral intestinal
metaplasia being one of the most prominent histological
characteristics. Bile reﬂux is also positively associated with
the severity of glandular atrophy, chronic inﬂammation,
lamina propria edema, and foveolar hyperplasia. As a result,
a histological index, the Bile Reﬂux Index (BRI score), was
derived to measure the severity of bile-induced histological
changes in the gastric antrum mucosa [16].
One of the most serious complications of GERD is
Barrett’s esophagus. It represents a premalignant condition
of the distal esophagus in which squamous epithelial cells are
replaced by metaplastic intestinal-like columnar epithelium
that contains goblet cells. Apoptosis seems to maintain
esophageal tissue homeostasis, which is regulated by p53,
and is gradually lost in the metaplasia-dysplasia-carcinoma
sequence of Barrett’s esophagus [17]. Similarly, apoptosis is
involved in gastric epithelial homeostasis and integrity since
its deregulation is associated with the occurrence of lesions
such as atrophic gastritis, peptic ulcers, intestinal metaplasia,
and gastric malignancies [18].
In a previous study, we reported that the presence of
bile reﬂux gastropathy in patients with GERD was associated
with more severe disease [19]. The aim of this study was
to investigate if the reﬂux of bile into the stomach and
the esophagus could be associated with apoptotic disorders
and abnormal oncogene expression. For this purpose, the
mucosal expression of the biomarkers p53, Ki-67, Bax, and
Bcl-2 was immunochistochemically examined.
2.MaterialsandMethods
Fifty-three patients (42 men and 11 women, mean age 33.3
years, range 18–76) with at least 12-week total duration
of reﬂux symptoms and a frequency of three times a
week/four hours a day during the last month, underwent
upper gastrointestinal (GI) endoscopy, after completing a
standardized questionnaire with demographic and clinical
details.
Exclusion criteria were (1) previous foregut surgery; (2)
treatment with nonsteroid anti-inﬂammatory or antiplatelet
drugs; (3) previous history of Helicobacter pylori(H. p.)
eradication; (4) portal hypertensive gastropathy or varices
(gastric or esophageal); (5) corrosive oesophagitis by a
toxicant; (6) alcohol abuse; (7) scleroderma; (8) active ulcer
disease;(9)neoplasiaorCrohn’sdiseaseoftheupperGItract;
(10) systematic use of PPIs.
Standard complete upper GI endoscopy was performed
with the Fujinon 250 HR gastroscope by the same endo-
scopist (A. Nakos) after a 12-hour fasting period. Reﬂux
oesophagitis was graded from A (least severe) to D (most
severe), according to the Los Angeles classiﬁcation system,
whereas hiatal hernia was considered if gastric folds were
extending ≥3cm above the diaphragmatic hiatus. After
detection of the lesions, two biopsies were taken from gastric
antrum, two from gastric body and cardia, and two from
the esophagus. The biopsies from the esophagus were taken
from its lowest 5cm, each specimen from the right and left
esophageal wall, respectively. In case of erosions, biopsies
were taken besides them. If Barrett’s esophagus was present,
both columnar and squamous epithelium were biopsied.
Control biopsies obtained from 15 healthy control (HC)
s u b j e c t s( 9m e na n d6w o m e n ,m e a na g e4 0 . 4y e a r s ,r a n g e
23–67) were without symptoms of GERD and no endoscopic
evidence of erosive oesophagitis or Barrett’s. Nine of the
healthy controls underwent endoscopy to exclude gastric
pathology and the other 6 were healthy volunteers. Informed
consent was obtained from each patient and healthy control
volunteer, and the study was approved by the local research
ethics committee.
All biopsy specimens were ﬁxed in 10% neutral formalin
for at least 3 hours, processed, sectioned at 4µm, and
stained by haematoxylin-eosin, alcian blue/periodic acid-
Schiﬀ (AB/PAS), and Giemsa. Histological examination,
based on the updated Sydney system included the investi-
gation for the presence of acute and chronic inﬂammation,
edema, and atrophy, H. pylori status, intestinal metaplasia,
dysplasia, and BE. Each ﬁnding was graded on a 0–3
scale (absent, mild, moderate, and marked, resp.) and the
BRI score was calculated in antral biopsies according to
the formula: (7×edema)+(3×IM)+(4×chronic inﬂam-
mation)−(6×H. pylori). Bile Reﬂux Index values above 14
are considered abnormal and give the best prediction of a
raised concentration of bile acid into the gastric juice [16].
Apart from the routine histological evaluation and the
BRI score calculation, four slides carrying two-sections each
were immunohistochemically examined for the p53, Ki-
67, Bax, and Bcl-2 expression (Biogenex Laboratories, Inc.,
San Ramon, Calif, USA). Bax and Bcl-2 were checked in
columnar epithelium only, which means in gastric mucosa
and in Barrett’s esophagus, whereas p53 and Ki-67 were
examined in all specimens. According to the percentages of
the stained epithelial cells, the immunohistological sections
were scored and graded as follows: 0 = absence of staining,
1 = staining up to 5%, 2 = staining >5%–10%, 3 = staining
>10%–25%, 4 = staining >25%–50%, and 5 = staining
>51%. The biopsies were assessed by one experienced GI
pathologist (E. Sivridis) who was unaware of the clinical
condition.
For the statistical analysis, continuous data are presented
as mean values along with 95% CI and categorical data are
presented as proportions. The patients and the HCs with
BRI score >14 were characterized as bile reﬂux positive (BRI
+) and those with BRI score ≤14 as bile reﬂux negative
(BRI −). In GERD patients, the two groups were at ﬁrst
compared for diﬀerences concerning demographic data,
clinical parameters, endoscopic, and histological ﬁndings.
Both groups were subsequently evaluated for diﬀerences
in immunohistochemical characteristics of the gastric and
esophageal mucosa, regarding the investigated biomark-
ers. Correlation and logistic regression analyses were also
performed in order to assess which demographic, clinical,
endoscopic, or histological parameters had signiﬁcant inﬂu-
ence on the severity of immunohistochemical expression
of the biomarkers in gastric and esophageal mucosa. In
these analyses we assumed immunohistochemical staining
grade 0–3 as score 0 and staining grade 4-5 as score 1.Gastroenterology Research and Practice 3
Furthermore, similar analyses were performed in the HC
group,anddiﬀerencesbetweenGERDpatientsandHCswere
alsoinvestigated.Thelevelofstatisticalsigniﬁcancewassetat
P<0.05.
3. Results
Demographic, clinical, endoscopic and histological data of
GERD patients and healthy controls are shown in Tables 1
and 2.T h eB R Is c o r ew a se l e v a t e d( >14) in 47.1% (25/53) of
the GERD patients (bile reﬂux positive group) and in 13.3%
(2/15) of the control subjects (Fisher’s exact two-tailed test;
P = 0.02). Additionally, GERD patients had lower BMI score
(Table 1),whereasgastritis,presenceofbileintothestomach,
atrophyandentericmetaplasiaweremorecommoningastric
endoscopy and histology in GERD patients as compared to
healthy controls (Table 2).
Demographic, clinical, endoscopic, and histological data
of BRI-positive and BRI-negative GERD patients are shown
in Tables 3 and 4.O v e r a l l ,s e v e r ee s o p h a g e a ll e s i o n s
(oesophagitis ≥ grade B and Barrett’s) were signiﬁcantly
more common in BRI (+) GERD patients (14/25) compared
to BRI (−) (5/28) (56% versus 17.9%, respectively, Fisher’s
exact two-tailed test; P = 0.0049). In 1 BRI (+) GERD
patient, both Barrett’s esophagus and severe oesophagitis
were simultaneously observed, while 2 patients had only
Barrett’s esophagus without esophagitis. Histological classi-
ﬁcation of the esophagitis was not used. In the vast majority
of cases, the inﬂammatory inﬁltration was mild and not
correlated with the endoscopic appearance. Its presence in
some control cases was also minimal (data not presented).
In patients with Barrett’s esophagus, the typical endoscopic
ﬁndings were also histologically conﬁrmed in all cases. None
of them had dysplastic epithelium. Furthermore, 13 out of
18 patients with GERD severe esophageal lesions had an
elevated Bile Reﬂux Index score (72,2%).
On the contrary, the results of the immunohistochemical
studies did not diﬀer between the BRI-positive and BRI-
negative GERD patients. We found absence of p53 staining
in the esophagus in 15 BRI (+) and 21 BRI (−) patients,
score 1 in 9 BRI (+) and 7 BRI (−) patients, and score 3
in 1 patient. In the control group, an absence or very low
expression of esophageal p53 was detected. There were no
signiﬁcant diﬀerences in esophageal mucosa p53 expression
between healthy controls and GERD patients, and/or BRI-
positive and BRI-negative subjects (Figure 1).
At the stomach, p53 staining was absent in the majority
of GERD patients, (in 47 out of 53; 88.6%; 21 BRI (+)
and 26 BRI (−) patients, resp.) and score 1 (≤5%) in 6
out of 53 (11.4%) GERD patients (4 BRI (+) and 2 BRI
(−) patients, resp.). In the control group, an absence or
very low expression of gastric p53 was also detected. There
were no signiﬁcant diﬀerences in gastric antrum mucosa
p53 expression between healthy controls and GERD patients,
and/or BRI-positive and BRI-negative subjects (Table 5).
Ki-67 staining was present in the esophageal epithelium
in almost all tissue samples either from BRI (+) or BRI
(−) GERD patients. However, low expression of esophageal
Ki-67 expression was detected in the majority of GERD
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Figure 1: Bax expression in gastric mucosa in healthy controls
(HCs) and GERD patients, in relation to BRI status. Grouped data
are presented in 100% display stacked columns for each grade (n;
%). According to the percentages of the stained epithelial cells, the
immunohistological sections were scored and graded as follows: 0 =
absence of staining, 1 = staining up to 5%, 2 = staining >5%–10%,
3 = staining >10%–25%, 4 = staining >25%–50%, and 5 = staining
>51%.
patients, as it also happened in the control group. There
were no signiﬁcant diﬀerences in esophageal mucosa Ki-
67 expression between healthy controls and GERD patients,
and/or BRI-positive and BRI-negative subjects.
Similarly, Ki-67 in the gastric mucosa was equally
expressedbetweenthetwoGERDgroups.Ontheotherhand,
low expression was detected in healthy controls, although
elevated (score 4) expression of Ki-67 was detected in 1
healthy BRI-positive subject. In general, there were no sig-
niﬁcant diﬀerences in esophageal mucosa Ki-67 expression
between healthy controls and GERD patients, and/or BRI-
positive and BRI-negative subjects (Table 6).
An overexpression of the biomarker Bax that promotes
apoptosis was noticed in the gastric mucosa. However, it was
not aﬀected by the level of BRI score. Increased expression
of Bax, as expected, was also noticed in HCs. There were
not signiﬁcant diﬀerences in gastric Bax expression between
healthy controls and GERD patients, and/or BRI-positive
and BRI-negative subjects (Figure 1).
Ontheotherhand,althoughtheantiapoptoticfactorBcl-
2 in antral mucosa was absent in 67.9% (36/53) of GERD
patients, an overexpression (score 5) was detected in 15%
(8/53) of them, without any association with the BRI levels
(equal expression in both groups). Furthermore, an absence
or very low expression of Bcl-2 was detected in the control
group. No signiﬁcant diﬀerences in gastric Bcl-2 expression4 Gastroenterology Research and Practice
Table 1: Demographic and clinical data in GERD patients and healthy controls.
GERD patients (n = 53) Healthy controls (n = 15)
Gender, n (M/F) 42/11 9/6
Age, mean (95% CI) 33.3 (29.2–37.3) 40.4 (31.2–49.5)
BMI
Mean (95% CI) 24.7 (23.6–25.3)∗ 26.85 (25.3–28.3)
Elevated (>25), n (%) 22 (41.5) 11 (73.3)
Smoking, n (%) 22 (41.5) 7 (46.6)
Statistically signiﬁcant diﬀerences are marked with asterisk (∗).
Table 2: Endoscopic and histologic data in GERD patients and
healthy controls.
GERD
patients
(n = 53)
Healthy
controls
(n = 15)
Esophagus
Endoscopy, n (%)
Esophagitis grade
0 20 (37.7) 15 (100)
A 15 (28.3) 0
B 13 (24.5) 0
C 3 (5.6) 0
D 00
Barrett’s 3 (5.6) 0
Hernia 18 (33.9) 4 (26.6)
Presence of bile 4 (7.5) 0
Histology, n (%)
Esophagitis 45∗ (84.9) 8 (53.3)
Barrett’s 3(5.6) 0
Dysplasia 00
Stomach
Endoscopy, n (%)
Gastritis
No 11 (20.7) 10 (66.6)
Mild 30∗ (56.6) 5 (33.3)
Erosive 12∗ (22.6) 0
Presence of bile 27∗ (50.9) 3 (20)
Histology, n (%)
Gastritis 50 (94.3) 10 (66.6)
Atrophy 17∗ (32) 1 (6.6)
H. pylori (yes) 16 (30.2) 3 (20)
Cardiac metaplasia 5 (9.4) 1 (6.6)
Antrum metaplasia 12∗ (22.6) 0
Dysplasia 00
Statistically signiﬁcant diﬀerences are marked with asterisk (∗).
between healthy controls and GERD patients, and/or BRI-
p o s i t i v ea n dB R I - n e g a t i v es u b j e c t sw e r ed e t e c t e d( Figure 2).
No association was also revealed between the presence of
Helicobacter pylori and the expression of the biomarkers in
the gastric mucosa (data not shown).
Table 3: Demographic and clinical data in BRI-positive and BRI-
negative GERD patients.
BRI-positive
(n = 25)
BRI-negative
(n = 28)
Gender, n (M/F) 16/9 26/2
Age, mean (95% CI) 37.96
(30.6–45.2)∗
29.18
(25.3–33)
BMI
Mean (95% CI) 24.2
(22.8– 25.6)
24.75
(23.7–25.8)
Elevated (>25), n (%) 10 (40) 12 (42.8)
Smoking, n (%) 10 (40) 11 (39.3)
Statistically signiﬁcant diﬀerences are marked with asterisk (∗).
Overall, correlation and regression analyses did not
reveal any signiﬁcant inﬂuence of demographic, clinical,
endoscopic, or histological parameters on the severity of
immunohistochemical ﬁndings in gastric and esophageal
mucosa (data not shown).
4. Discussion
The gastro-esophageal reﬂux disease is pathogenetically
associated with both acid and bile reﬂux. The synergism
betweenacidandduodenalcontentshasbeenassociatedwith
signiﬁcant esophageal injury and progression of metaplasia
to Barrett’s esophagus [20–22]. Although the majority of
patients with GERD have no esophageal lesions (NERD),
a signiﬁcant proportion develops oesophagitis, whereas
Barrett’s is diagnosed in about 10% of patients.
The duodeno-gastroesophageal reﬂux nowadays, is
quantitatively evaluated by highly sophisticated and reliable
methods such as Bilitec 2000 or the multichannel intralumi-
nalimpedance[23].However,bilereﬂuxisalsohistologically
evaluated according to the bile-induced reactive gastropathy
and expressed by the Bile Reﬂux Index [24].
In a previous study, we used the BRI score and found
that about half of GERD patients had histological lesions
due to bile reﬂux into the stomach and that BRI score was
associated with the endoscopic severity of the esophageal
disorder. Consequently, evaluating the histological evidence
of bile reﬂux in the stomach, we indirectly showed the
implication of duodeno-gastroesophageal reﬂux (DGER) in
the pathogenesis of GERD [19].Gastroenterology Research and Practice 5
Table 4: Endoscopic and histologic data in BRI-positive and BRI-
negative GERD patients.
BRI-positive
(n = 25)
BRI-negative
(n = 28)
Esophagus
Endoscopy, n (%)
Esophagitis Grade
0 7 (28) 13 (46.4)
A 5 (20) 10 (35.7)
B 8 (32) 5 (17.8)
C 3 (12) 0
D 00
Barrett’s 3 (12) 0
Hernia 10 (40) 8 (28.5)
Presence of bile 2( 8 ) 2( 7 )
Histology, n (%)
Esophagitis 22 (88) 23 (82.1)
Barrett’s 3 (12) 0
Dysplasia 00
Stomach
Endoscopy, n (%)
Gastritis
No 3 (12) 8 (28.5)
Mild 15 (60) 15 (53.5)
Erosive 7 (28) 5 (17.8)
Presence of bile 13 (52) 14 (0.5)
Histology, n (%)
Gastritis 24 (96) 26 (92.8)
Atrophy 11 (44) 6 (21.4)
H. pylori 3∗ (12) 13 (46.4)
Cardiac metaplasia 5 (20) 1 (3.5)
Antrum metaplasia 9∗ (36) 3 (10.7)
Dysplasia 00
Statistically signiﬁcant diﬀerences are marked with asterisk (∗).
In this study and in the same group of patients, we
evaluated the mucosal expression of tumor and apoptotic
markers using immunohistochemical methods. The aim
was to investigate possible associations existing between
GERD/DGER and the early stages of carcinogenesis. For this
purpose, the mucosal expression of the biomarkers p53, Ki-
67, Bax, and Bcl-2 was evaluated.
p53 is a tumor suppressor gene which encodes a nuclear
protein that plays an important role in cell cycle control,
DNA synthesis and repair, cell diﬀerentiation, and apoptosis.
Mutant forms of p53 gene are usually associated with
accumulation of the protein in the cell, which can be
detected by using speciﬁc antibodies [25]. Bcl-2 protein
prolongs cell survival and is considered to be a suppressor of
apoptosis whereas Bax protein plays a key role in apoptosis
by accelerating cell death after an apoptotic stimulus. Ki-67
is a nuclear antigen that is present in proliferating cells and it
has been used as an index of cell proliferation [26–29].
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Figure 2: Bcl-2 expression in gastric mucosa in healthy controls
(HC) and GERD patients, in relation to BRI status. Grouped data
are presented in 100% display stacked columns for each grade (n;
%). According to the percentages of the stained epithelial cells, the
immunohistological sections were scored and graded as follows: 0 =
absence of staining, 1 = staining up to 5%, 2 = staining >5%–10%,
3 = staining >10%–25%, 4 = staining >25%–50%, and 5 = staining
>51%.
Although Barrett’s esophagus and esophageal adenocar-
cinoma have extensively been studied with immunohisto-
chemical methods, there is a lack of immunohistochemical
studies for benign disorders such as erosive oesophagitis
or NERD in association or not with DGER [30, 31]. On
the other hand, the association between DGER, GERD
and, carcinogenesis is constantly suggested and in a recent
study Shaheen and Ransohoﬀ reported that the risk of
esophageal adenocarcinoma is increased ﬁvefold in patients
with previously diagnosed oesophagitis. However, most of
theadenocarcinomasoccurredamongpatients withBarrett’s
esophagus [32].
Numerous studies and animal models have shown the
carcinogenetic eﬀect and mutagenic potential of DGER in
the esophageal mucosa. The mechanism is probably indirect,
involving the induction of oxidative stress and production
of reactive oxygen species that damage DNA. Repeated DNA
damage likely increases the mutation rate, including the
mutationrateoftumorsuppressorgenesandoncogenes[33–
35].
Inthepresentstudy,weimmunohistochemicallydemon-
strated a minimal oncogene expression, suggesting that the
potential risk for esophageal carcinogenesis in patients with
GERD is extremely low regardless of bile reﬂux contribution.
Speciﬁcally, the very low expression of p53 in the esophageal
specimens, with staining cells up to 5% in 96.10% of patients6 Gastroenterology Research and Practice
Table 5: Immunohistochemical study of the p53 expression in esophageal and gastric mucosa of GERD patients and HCs.
GERD (n = 53) Healthy controls (n = 15)
Grade of p53 staining
(n)
Esophagus Stomach Esophagus Stomach
BRI (+)
(n = 25)
BRI (−)
(n = 28)
BRI (+)
(n = 25)
BRI (−)
(n = 28)
BRI (+)
(n = 2)
BRI (−)
(n = 13)
BRI (+)
(n = 2)
BRI (−)
(n = 13)
0 1 52 12 12 6 2 1 0 2 1 1
19 7 4 2 — 3 — 2
2 ————————
3 1 ———————
4 ————————
5 ————————
According to the percentages of the stained epithelial cells, the immunohistological sections were scored and graded as follows: 0 = absence of staining, 1 =
staining up to 5%, 2 = staining >5%–10%, 3 = staining >10%–25%, 4 = staining >25%–50%, and 5 = staining >51%.
Table 6: Immunohistochemical study of the Ki-67 expression in esophageal and gastric mucosa of GERD patients and HCs.
GERD (n = 53) Healthy controls (n = 15)
Grade of Ki-67 staining
(n)
Esophagus Stomach Esophagus Stomach
BRI (+)
(n = 25)
BRI (−)
(n = 28)
BRI (+)
(n = 25)
BRI (−)
(n = 28)
BRI (+)
(n = 2)
BRI (−)
(n = 13)
BRI (+)
(n = 2)
BRI (−)
(n = 13)
0 ————————
1 1 71 71 11 7 1 9 1 9
23 3 4 — 1 3 — 3
32 5 3 5 — 1 — 1
43 2 4 3 — — 1 —
5— 1 3 3 — — — —
According to the percentages of the stained epithelial cells, the immunohistological sections were scored and graded as follows: 0 = absence of staining, 1 =
staining up to 5%, 2 = staining >5%–10%, 3 = staining >10%–25%,4 = staining >25%–50%, and 5 = staining >51%.
(52/53), means that the mutation rate of the p53 gene,
which is considered one of the most serious initial events
in tumorigenetic process, was not increased. Even low p53
protein expression was unrelated with the presence of bile
reﬂux gastropathy, the levels of BRI score or the endoscopic
severity of the esophageal lesions. Previous studies have
demonstrated that positive rates of p53 protein expression in
esophageal mucosa were gradually increased from normal to
reﬂux oesophagitis and furthermore to Barrett’s metaplasia
and dysplasia [36].
As it has been mentioned above, the accumulation of
p53 protein in the cell is highly suggestive for p53 gene
mutation. However, positive p53 immunostaining in some
tissue samples is related to inactivation of p53 protein by
diﬀerent mechanisms than the mutation of p53 gene, such as
mucosal inﬂammation. The histological examination of the
esophageal biopsies of our patients revealed the presence of
mild to moderate chronic inﬂammation in the majority of
them (45/53; 84.9%,Tables 2 and 4) and this phenomenon
could be related with the low expression of p53 in our GERD
patients. In that case, the low p53 expression in our cases
has practically no carcinogenetic eﬀect because it is probably
associated with the inﬂammation and not with mutations
[37].
Regarding the Ki-67 cell proliferation marker, we found
a very low esophageal expression in 64.1% (45/53) of our
patients. Similarly, Feith et al. investigating the malignant
degeneration of Barrett’s esophagus showed that there was
a low expression of Ki-67 in normal squamous epithelium of
the esophagus (only 20.4±6.4% of cells were Ki-67-positive)
compared to columnar metaplasia (34.9 ± 11.1%), dysplasia
(44.8 ± 8.9%), and invasive carcinoma (60.8 ± 17.9%) [38].
We found no statistically signiﬁcant associations between Ki-
67 reactivity either with the BRI positivity or the severity
of the esophageal lesions, even in the 6 cases (11.3%) with
moderate or high Ki-67 expression (>25% of cells stained).
As it has been detected, the presence of bile reﬂux gas-
tropathy in our GERD patients was not associated with p53
orKi-67expressionintheesophagealmucosa.Consequently,
bile reﬂux seems not to change the theory that there is a
lack of genetic susceptibility markers for the development
and early progression of GERD to Barrett’s esophagus and
esophageal cancer [39].
In accordance with the esophagus, we found no associa-
tion between the bile reﬂux gastropathy and deregulation of
apoptosis or oncogene expression in the gastric mucosa.
The very low expression of p53 in the gastric mucosa
in a small number of patients is also suggestive that an
accumulation of wild-type protein occurred, probably due
to an inﬂammatory response. Our ﬁndings are compatible
with Craanen et al.’s study who described an absence of p53
expression in benign gastric lesions [40]. However, manyGastroenterology Research and Practice 7
Figure 3: Ki-67 expression in the gastric mucosa (magniﬁcation
×100). The immunoreactive cells (dark nuclei) are mainly located
at the base of the epithelium.
investigators have already supported that H. pylori infection
is associated with the increased expression of p53 in gastric
mucosa [41, 42].
Furthermore, the high expression of the Bax protein in
the gastric mucosa of our patients is indicative that the
process of apoptosis is not aﬀected and it plays an important
protecting role against carcinogenesis. Similarly, the Ki-67
immunoreactivecellsofourpatientsweremainlylocalizedat
the base of the epithelium, which correspond to the naturally
occurring proliferative zone (Figure 3).
An overexpression of the Bcl-2 protein at the stomach
was detected in 15% of our patients. However, it was not
statistically associated either with the bile reﬂux gastropathy
or with the H. pylori infection. Moreover, regression analyses
did not reveal any signiﬁcant inﬂuence of demographic, clin-
ical, endoscopic, or histological parameters on the severity of
immunohistochemical expression the speciﬁc antiapoptotic
marker in gastric mucosa. However, in contrast with our
ﬁndings, the signiﬁcance of Bcl-2 expression at the stomach
has been previously reported and found to be implicated
in the multistep process, ranging from chronic gastritis to
atrophy, intestinal metaplasia, dysplasia, and ﬁnally invasive
gastric cancer [43].
5. Conclusions
To summarize, we could say that our study demonstrated
that, although the bile reﬂux signiﬁcantly contributes in the
pathogenesis of GERD, it has practically no impact on the
process of apoptosis or primary carcinogenetic eﬀect in the
upper GI mucosa of these patients. However, the fact that
the patients of our study are relatively young is indicating
a conscious interpretation of the results, especially as far
as the immunohistochemistry is concerned. On the other
hand, larger series of patients and probably more speciﬁc
and sensitive methods of evaluation of bile reﬂux, than
histologicalevidenceonly,areneededinordertoevaluatethe
signiﬁcance of our ﬁndings.
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